11/12/2019 4:12:57 PM
Inovio Pharma Q3 Loss/share $0.25 Vs. Loss $0.27 Year Ago
11/5/2019 8:10:20 AM
Inovio Shows 80% 6-Month PFS In Phase 2 GBM Study With INO-5401 In Combination With PD-1 Inhibitor Libtayo
9/17/2019 9:03:45 AM
Inovio Gets NIH Funding To Target Its DMAb Technology Against Antimicrobial-Resistant Infection
8/8/2019 4:11:28 PM
Inovio Pharma Q2 Loss/share $0.30 Vs. Loss $0.08 Year Ago
8/6/2019 4:16:44 PM
Inovio Closes $15 Mln Private Placement Of Convertible Bonds To Institutional Investors In Korea
7/25/2019 9:02:11 AM
Inovio's Positive First-in-Human MERS Vaccine Results Published In Lancet Infectious Diseases
7/10/2019 8:02:39 AM
Geneos Therapeutics Says First Patient Dosed With DNA-based, Neoantigen-Targeting Personalized Vaccine Technology
7/8/2019 9:02:02 AM
Inovio Completes Enrollment In Its Phase 2 Trial With VGX-3100
6/26/2019 9:15:04 AM
Inovio Closes Enrollment Of VGX-3100 Phase 3 Trial For Treatment Of HPV-Related Cervical Pre-cancer
6/10/2019 9:04:16 AM
Inovio Bags $8.14 Mln Award To Support Further Development Of Commercial Skin Delivery Device
5/21/2019 9:02:37 AM
Inovio Doses Subjects In Phase 1, First-in-human Clinical Trial To Evaluate INO-4500
5/9/2019 4:10:27 PM
Inovio Pharma Q1 Loss/share $0.30 Vs. Loss $0.36 Year Ago
5/6/2019 9:10:31 AM
Inovio Gets European Medicines Agency Certification For Quality And Non-Clinical Data For Phase 3 Product, VGX-3100